Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • TUMORS  (6)
  • 1
    Keywords: EXPRESSION ; tumor ; carcinoma ; CELL ; Germany ; TYROSINE KINASE ; screening ; SITE ; SITES ; DISTINCT ; microarray ; PROTEIN ; TISSUE ; TUMORS ; primary ; GROWTH-FACTOR RECEPTOR ; FREQUENCY ; FREQUENCIES ; STAGE ; PROGRESSION ; immunohistochemistry ; ABERRATIONS ; HEAD ; ONCOPROTEIN ; CARCINOMAS ; NECK ; squamous cell carcinoma ; GREECE ; gene amplification ; head and neck ; laryngeal carcinoma ; OROPHARYNGEAL ; C-MYC ; CANCER PATIENTS ; CYCLIN D1 OVEREXPRESSION ; cytogenetic aberration ; head and neck squamous cell carcinoma (HNSCC) ; immunohistochemistry (IHC) ; MICROARRAY ANALYSIS ; oncoprotein overexpression ; OVEREXPRESSION ; POOR-PROGNOSIS ; tissue microarray (TMA) ; tumor classification
    Abstract: Background: Tissue microarray (TMA) analysis is a high-throughput approach that allows the screening of large tumor collectives for cytogenetic aberrations. In this study, a TMA of a large collection of clinically well-defined primary squamous cell carcinomas of the head and neck (HNSCC) was used to determine the expression of several oncoproteins. Materials and Methods: A TMA containing 547 primary HNSCC was used for the analysis of cyclinD1, c-myc, erbb1 and erbb2 expression by immunohistochemistry (IHC). Results: CyclinD1 and c-myc were overexpressed at higher frequencies in primary pharyngeal and laryngeal carcinomas compared with primary oral carcinomas (p 〈 0.001 and p 〈 0.001), while erbb1 and erbb2 overexpression was associated with oral site (p 〈 0.001 and p = 0.04, respectively). Furthermore, cyclinD1 overexpression correlated with stage IV primary carcinomas (p = 0.04). Conclusion: HNSCC is a heterogenous group of tumors, which, depending on anatomic sites and clinical stage, shows variable expressions of the oncoproteins described. This indicates a specific pathogenic role of these oncoproteins in different subtypes of HNSCC and may have therapeutic implications
    Type of Publication: Journal article published
    PubMed ID: 14666705
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CANCER ; CELLS ; tumor ; carcinoma ; Germany ; THERAPY ; TUMORS ; PATIENT ; treatment ; 5-FLUOROURACIL ; ASSAY ; chemotherapy ; EPITHELIAL-CELLS ; HEAD ; NECK ; squamous cell carcinoma ; PREDICTION ; sensitivity ; head and neck carcinoma ; HNSCC ; INFUSION ; SOLID TUMORS ; COLONY FORMATION ; chemosensitivity testing ; head and neck squamous cell carcinoma ; SPECIMENS ; 5-FU ; drug combinations ; tumor stroma
    Abstract: Previous studies focusing on response prediction to chemotherapy by chemosensitivity testing of tumor explants has focused on the response determination of single cytostatic drugs, in contrast to the common clinical application of cytostatic drug combinations. Therefore, the present study was aimed at determining the quantitative ex vivo chemoreactivity of epithelial cells from head and neck squamous cell carcinoma (HNSCC) specimens to cytostatic drug combinations. Specimens from 12 histologically-confirmed HNSCC were investigated. According to a previously established ex vivo colony formation assay, the individual cellular chemoreactivity was determined quantitatively for combinations of 4 cytostatic drugs: cis-platinum (cis-DDP), carboplatin (CBDCA), 5-Fluorouracil (5-FU) and docetaxel (DTX). The tests were performed using drug combinations according to recent clinical therapy regimens in the treatment of solid tumors: i) cis-DDP + 5FU, ii) CBDCA + 5FU, iii) cis-DDP + DTX and iv) CBDCA + DTX The approach provides individual drug response patterns of epithelial as well as of stromal cells. Individual, selective sensitivities were found for each drug combination tested. The stromal and epithelial chemoreactivity profiles differed in most of the specimens. Moreover, stromal cell chemoresistance dominated selective epithelial chemosensitivities in the majority of cases. The determination of the epithelial ex vivo chemoreactivity identified individual chemosensitivities which were verified by the clinical history of the patient. Therefore, the described protocol to determine the ex vivo chemoresponse of HNSCC specimens to cytostatic drug combinations may help to provide clinicaly useful information concerning the individual chemoresponse of HNSCC with regard to individualization of oncological decision making
    Type of Publication: Journal article published
    PubMed ID: 16619587
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    facet.materialart.
    facet.materialart.
    Anticancer Research 23 (2C), 1769-1772 
    Keywords: CANCER ; CANCER CELLS ; CELLS ; EXPRESSION ; tumor ; SITES ; microarray ; DRUG ; TUMORS ; PATIENT ; DNA ; mechanisms ; GLYCOPROTEIN ; DNA microarray ; DNA microarray technology ; c-Fos ; CROSS-RESISTANCE ; drug resistance ; MULTIDRUG-RESISTANCE ; protooncogenes ; CELL LUNG CARCINOMAS ; DEFICIENT ACTIVATION ; DETOXIFYING ENZYMES ; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE ; resistance-related proteins ; S-TRANSFERASE-PI
    Abstract: Drug resistance is an important problem in the treatment of patients with cancer. Tumors become resistant not only to the drugs used initially, but also to those to which they have not yet been exposed. Multiple mechanisms contribute to drug resistance. Many of them are inter-related or independent Of each other, but may exist simultaneously in cancer cells or subpopulations of cells, producing an overall drug-resistant phenotype. Consequently, clinical reversal of drug resistance may ultimately require intervention at several different sites in the tumor cell. In the future, the use of DNA microarray technology in drug resistance in cancer will yield insight into the mechanisms of drug resistance and the rational design of more effective strategies to circumvent resistance
    Type of Publication: Journal article published
    PubMed ID: 12820456
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: CELLS ; IN-VITRO ; tumor ; carcinoma ; CELL ; evaluation ; Germany ; LUNG ; VIVO ; GENERATION ; INFORMATION ; TUMORS ; PATIENT ; IMPACT ; 5-FLUOROURACIL ; ASSAY ; resistance ; HEAD ; NECK ; squamous cell carcinoma ; GREECE ; head and neck ; MULTIDRUG-RESISTANCE ; INDUCTION CHEMOTHERAPY ; CELL CARCINOMA ; ORGAN PRESERVATION ; ADVANCED LARYNGEAL-CANCER ; DRUG-RESPONSE ASSAY ; head and neck carcinoma,HNSCC,chemosensitivity testing,tumor stroma,ex vivo culture ; P-GLYCOPROTEIN ; PROGNOSTIC IMPACT ; SENSITIVITY ASSAYS ; TUMOR VOLUME
    Abstract: Background: Reliable chemosensitivity testing of head and neck squamous cell carcinoma (HNSCC) still faces methodical limitations. Since stromal cell contamination has been found to preclude reliable radiosensitivity testing of HNSCC as well as chemosensitivity testing of lung tumors, the present study investigates the impact of stromal cell contamination on chemosensitivity testing of HNSCC Patients and Methods: Seventeen biopsies from HNSCC were analyzed The specimens were investigated using an ex vivo colony formation assay which allows for the quantitative and separate determination of the overall, as well as the epithelial, and stromal response to carboplatin, 5-fluorouracil and docetaxel. Results: The overall chemoresponse was dominated by stromal cell multidrug resistance. However, by selective evaluation of the epithelial chemoresponse, individual chemosensitivity patterns could be identified Conclusion: Multidrug-resistant stromal cells preclude the reliable assessment of the chemoresponse of HNSCC specimens. Careful correction for stromal cell effects is a prerequisite for the generation of therapeutically useful information
    Type of Publication: Journal article published
    PubMed ID: 15015616
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    Keywords: APOPTOSIS ; CANCER ; proliferation ; SURVIVAL ; tumor ; carcinoma ; CELL ; CELL-PROLIFERATION ; Germany ; LUNG ; MODEL ; lung cancer ; VOLUME ; DEATH ; DISEASE ; HEPATOCELLULAR-CARCINOMA ; TUMORS ; ANTIGEN ; NO ; IN-SITU ; PROGRESSION ; immunohistochemistry ; CARCINOMAS ; BODY ; LUNG-CARCINOMA ; SECTIONS ; VOLUMES ; BODIES ; END ; TUMOR VOLUME ; lung tumors ; cell proliferation ; BALANCE ; SUBTYPE
    Abstract: To evaluate the relationship between cell proliferation and apoptosis during progression of lung carcinomas, immunohistochemistry for proliferating cell nuclear antigen (PCNA) and the in situ end labelling (TUNEL) method for identifying apoptotic bodies were performed on paraffin sections front 135 lung carcinomas. These results were correlated with the corresponding tumor volumes as a model of disease progression in lung tumors. We found that, with increasing tumor volume, the proliferation rate decreased significantly, whereas the apoptotic rate increased. There was no relationship between apoptotic and proliferative indices except in carcinomas with a tumor volume between 51 and 100 cm(3). These data suggest that progression of lung carcinomas, i.e. the increase in tumor volume, is accompanied by an increase in apoptosis rather than an increase in cell proliferation
    Type of Publication: Journal article published
    PubMed ID: 15736479
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    Keywords: CELLS ; EXPRESSION ; GROWTH ; SURVIVAL ; tumor ; CELL ; Germany ; human ; LUNG ; LUNG-CANCER ; SUPPORT ; DISEASE ; SITES ; TUMORS ; SURGERY ; PATIENT ; TISSUES ; BIOLOGY ; DOWN-REGULATION ; ASSOCIATION ; BONE-MARROW ; METASTASIS ; PROSTATE-CANCER ; MELANOMA ; ADHESION ; TRANSFORMATION ; MALIGNANT TRANSFORMATION ; adenocarcinoma ; non-small cell lung cancer ; cell adhesion ; development ; ELEVATED EXPRESSION ; BONE ; CELL-ADHESION MOLECULE-1 ; PROGRESSION-FREE SURVIVAL ; MARROW ; CEACAM1 ; prognostic significance ; grading ; Melanocyte ; CEACAM-1 ; ANTIGEN GENE FAMILY ; BILIARY GLYCOPROTEIN ; CD66A BGP ; hematogenous ; lymphnode
    Abstract: Background: CEACAM-1 is involved in intercellular adhesion and is expressed in a variety of human tissues. In cases of malignant transformation, a down-regulation or loss of CEACAM-1 has been shown. In contrast, CEACAM-1 is not expressed in normal lung tissue or melanocytes. It has been demonstrated that an expression in these tissues is associated with the development of metastatic disease. The aim of the present investigation was to analyze a possible association between the expression of CEACAM-1 in pulmonary adenocarcinomas and their lymph node and hematogenous metastatic cells. Patients and Methods: CEACAM-1 expression was immunhistochemically evaluated in primary tumors, lymph nodes and distant metastases of 96 patients with metastatic pulmonary adenocarcinoma who had undergone surgery between 1999 and 2002. Results: Expression of CEACAM-1 was shown in 78 out of 96 primary tumors (81.3%). A significant positive correlation was found between CEACAM-1 expression on cells of the primary tumor, lymph node metastases (p〈0.005) and hematogenous metastases (p=0.03). CEACAM-1 expression did not correlate with stage, gender, grading or patients' age. Compared to patients with tumors not expressing CEACAM-1, patients with a CEACAM-1-expressing tumor had a shorter median overall survival (21 vs. 28 months) and progression-free survival (11.7 vs. 16.3 months). Conclusion: CEACAM-1 is expressed in most primary pulmonary adenocarcinomas. This investigation demonstrates that its expression is preserved in lymph node and hematogenous metastases, indicating that its expression is of functional significance for both metastatic sites. These results support the prognostic relevance of the expression of CEACAM-1 in pulmonary adenocarcinoma
    Type of Publication: Journal article published
    PubMed ID: 19331157
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...